Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer

<div>Immunocytochemistry staining showing strong positivity for PD-L1.</div>

Case Reports in Endocrinology

Figure 4: Pembrolizumab in a Patient with Treatment-Naïve Unresectable BRAF-Mutation Negative Anaplastic Thyroid Cancer 